Urology
Volume 68, Issue 2, Supplement , Pages 9-16, August 2006

Development and validation of patient-reported outcomes measures for overactive bladder: A review of concepts

  • Karin S. Coyne

      Affiliations

    • Center for Health Outcomes Research, United BioSource Corporation, Bethesda, Maryland, USA
    • Corresponding Author InformationReprint requests: Karin S. Coyne, PhD, MPH, United BioSource Corporation, 7101 Wisconsin Avenue, Suite 600, Bethesda, Maryland 20814.
    • Karin S. Coyne is a consultant to Pfizer Inc.
  • ,
  • Andrea Tubaro

      Affiliations

    • Sant’Andrea Hospital, “La Sapienza” University, Rome, Italy
  • ,
  • Linda Brubaker

      Affiliations

    • Departments of Obstetrics, Gynecology, and Urology, Loyola University Medical Center, Maywood, Illinois, USA
    • Linda Brubaker receives research funding from Q-Med, Pfizer Inc, and Allergan and receives consultant/speaker honoraria from Q-Med, Novartis, Pfizer Inc, and Astellas.
  • ,
  • Tamara Bavendam

      Affiliations

    • Pfizer Inc, New York, New York, USA
    • Tamara Bavendam is an employee of Pfizer Inc.

Abstract 

Patient-reported outcome (PRO) measures are a valuable means for determining how a disease and its treatment affect patients, including effects on health-related quality of life (HRQL). To ensure that the results obtained with PROs are clinically useful, data must be gathered using valid and reliable instruments. Developing such instruments requires a multistep, structured process that incorporates cognitive psychology, psychometric theory, and patient and clinician input. The process begins by determining the intent and purpose of the PRO and culminates in studies that demonstrate the measure’s validity, reliability, and responsiveness. Several valid and reliable PROs are available for assessing the effects of treatment on symptom severity, symptom bother, and HRQL in patients with overactive bladder.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0090-4295(06)00770-9

doi:10.1016/j.urology.2006.05.042

Urology
Volume 68, Issue 2, Supplement , Pages 9-16, August 2006